Clinical trials: BACTERIAL VAGINOSIS
Bacterial Vaginosis
Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219
This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.
- Trial name
- NCT02452866
- Testing
- SYM-1219
- Where
- 40 sites in United States
- Volunteers
- 325 people
- Sponsor
- Symbiomix Therapeutics
Vulvovaginal Candidiasis
Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis
The purpose of this study is to compare the efficacy and safety of LactiSal 1%vaginal gel and LactiSal 50 mg vaginal tablet with the standart treatment of clotrimazole 100 mg vaginal tablet in woman with vulvovaginal candidiasis…
- Trial name
- NCT02907307
- Testing
- LactiSal vaginal gel 1%, LactiSal vaginal tablet 50mg, Clotrimazole vaginal tablet 100mg
- Sponsor
- Medinova AG
Bacterial Vaginosis (BV)
Multistrain Probiotics Against Bacterial Vaginosis
The primary aim of the study is to clarify whether and to what extent the consumption of the multistrain probiotic OMNi-BiOTiC® FLORA plus+ has a positive effect on the vaginal flora and reduces BV.
- Trial name
- NCT06888518
- Testing
- OMNi-BiOTiC® FLORA plus+, antibiotic
- Where
- Austria
- Volunteers
- 56 people
- Sponsor
- Institut AllergoSan Pharma GmbH
Bacterial Vaginosis
Pharmacokinetic Study of DARE-BV1
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT05354050
- Testing
- DARE-BV1
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Bacterial Vaginosis, Yeast Infection
A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.
This virtual randomized controlled trial evaluates the efficacy of a prebiotic and probiotic supplement in providing relief from symptoms associated with bacterial vaginosis and yeast infections.
- Trial name
- NCT06665126
- Testing
- Prebiotic + Probiotic Supplement
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Happy V
Bacterial Vaginosis, Vaginal Candidiasis
Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis
The goal of this clinical trial is to assess the safety and efficacy of Multi-Gyn Femitotal to treat and prevent women suffering from bacterial vaginosis and vulvo vaginal candidiasis.
- Trial name
- NCT07234786
- Testing
- Multi-Gyn FemiTotal
- Where
- Mauritius
- Volunteers
- 80 people
- Sponsor
- Karo Pharma AB
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03561701)
- Testing
- Oteseconazole (VT-1161)
- Where
- 14 sites in United States
- Volunteers
- 425 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Bacterial Vaginosis
Safety and Efficacy Study to Treat Bacterial Vaginosis
The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.
- Trial name
- NCT01621399
- Testing
- Product 55394
- Where
- 37 sites in United States
- Volunteers
- 651 people
- Sponsor
- Medicis Global Service Corporation
Vulvovaginal Candidiasis (VVC)
An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph.
- Trial name
- NCT07405853
- Testing
- pHyph
- Where
- 3 sites in Sweden
- Volunteers
- 48 people
- Sponsor
- Gedea Biotech AB
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis
- Trial name
- NCT05074602
- Testing
- SHR8008, Fluconazole
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Candidiasis, Vulvovaginal
Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis
- Trial name
- BLOSSOM (NCT07521137)
- Testing
- OCF001 Intravaginal Gel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sano Chemicals Inc
Bacterial Vaginosis (BV), Recurrent Bacterial Vaginosis
Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.
This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.
- Trial name
- Vagitab (NCT06725888)
- Testing
- Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- S.I.I.T. Srl
Bacterial Vaginoses
A User Study With Vernivia® for Bacterial Vaginosis.
This is an open user study to evaluate D005 vagnial mousse with regards to user-friendliness, and measure time from start of treatment to symptom relief and measure the clarity of instructional material.
- Trial name
- USV01 (NCT06104098)
- Testing
- D005 vaginal mousse
- Where
- 7 sites in Sweden
- Volunteers
- 76 people
- Sponsor
- PepTonic Medical AB
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and…
- Conditions
- BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe
- Trial name
- NCT02210689
- Testing
- clindamycin phosphate vaginal cream 2%
- Where
- 18 sites in United States, Dominican Republic and 1 more
- Volunteers
- 604 people
- Sponsor
- Actavis Inc.
Vulvovaginal Candidiasis
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of…
- Trial name
- NCT00803738
- Testing
- Terconazole Vaginal Suppository, Terazol Vaginal Suppository
- Volunteers
- 572 people
- Sponsor
- Padagis LLC
Bacterial Vaginosis (BV)
WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 150 pre-menopausal women with bacterial vaginosis (BV). Participants will be randomized 1:1:1 to three groups.
- Trial name
- NCT07888699
- Testing
- High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole
- Where
- 14 sites in China
- Volunteers
- 150 people
- Sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.
Bacterial Vaginosis, Vaginal Infection
Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis
The goal of this clinical trial is to show the efficacy and safety of dequalinium chloride in the treatment of bacterial vaginosis compared to metronidazole.
- Conditions
- Bacterial Vaginosis, Vaginal Infection, Vaginal Diseases
- Trial name
- NCT05788991
- Testing
- Dequalinium Chloride, Metronidazole Oral
- Where
- 14 sites in Czechia, Poland and 1 more
- Volunteers
- 151 people
- Sponsor
- Medinova AG
Bacterial Vaginosis
Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis
The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal®…
- Trial name
- NCT01020396
- Testing
- Metronidazole
- Where
- 37 sites in United States
- Volunteers
- 579 people
- Sponsor
- Teva Pharmaceuticals USA
Vaginitis
Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis
Open prospective multicenter phase IV study in patients presenting with symptoms of bacterial and/or mycotic (mushroom) vaginitis for 12 days as specified in the product information.
- Trial name
- NCT02444481
- Testing
- Polygynax combinaison of polymyxin, Neomycin and Nystatin
- Volunteers
- 169 people
- Sponsor
- Laboratoire Innotech International
Candidiasis, Vulvovaginal, Mycoses
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
The purpose of this study is to determine if two topical formulations of CD101 are safe and effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC) compared to oral fluconazole.
- Conditions
- Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal
- Trial name
- NCT02733432
- Testing
- CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%)
- Where
- 24 sites in United States
- Volunteers
- 126 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)